Target intelligence / Profile preview

Tumor protein p53 Tyr220Cys mutant (TP53 Y220C) (TP53 Y220C)

Target
TP53 Y220C
Molecular classification
Transcription factor
01

Overview

TP53 Y220C refers to the tumor protein p53 with a tyrosine-to-cysteine substitution at position 220, a recurrent hotspot mutation in cancers including AML and MDS. This structural mutation creates a unique hydrophobic surface crevice or pocket in the DNA-binding domain, reducing thermal stability (melting at physiological temperatures), impairing DNA binding, promoting denaturation and aggregation, and abrogating wild-type p53 tumor suppressor functions. Small molecules like PC14586 bind this pocket to refold the protein into wild-type-like conformation, reactivate transcriptional targets (e.g., MDM2, p21), and induce signaling, though full apoptotic efficacy requires combinations targeting MDM2, XPO1, or BCL-2 due to mechanistic limitations. The query specifies a "TP53 Y220C/HLA complex," but no search results describe such a complex; available data focus solely on the isolated mutant p53 protein or its small-molecule-bound structures (e.g., PDB 6GGC), indicating the complex may be non-standard, hypothetical, or undocumented here.

Other names
p53 Y220Cp53 cancer mutant Y220Cmutant p53-Y220C
02

Mechanism of action

Binds hydrophobic pocket created by Y220C mutation to stabilize wild-type conformation, Restore p53 transcriptional activity, Increase thermal stability, Decrease aggregation, Reactivate p53 signaling

03

Biological functions

DNA bindingTumor suppressionCell cycle arrestApoptosisDNA repair
04

Disease associations

CancerAcute myeloid leukemiaMyelodysplastic syndromes
05

Safety considerations

Limited apoptosis induction despite conformational restoration due to MDM2 upregulationXPO1-mediated nuclear exportLack of direct binding to BCL-2/BCL-xL/MCL-1Potential selection of non-Y220C TP53 clonesOff-target toxicity in some non-Y220C cell linesCo-mutations like TP53 P151A or NRAS may confer resistance
06

Interacting drugs

PC14586 (rezatapopt)

8 more in the full profile.

07

Biomarkers

TP53 Y220C mutation (hotspot for patient selection in AML/MDS and solid tumors)

Beyond the preview

Go deeper on Tumor protein p53 Tyr220Cys mutant (TP53 Y220C) (TP53 Y220C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor protein p53 Tyr220Cys mutant (TP53 Y220C) (TP53 Y220C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call